Home › Trials › NCT05919511

Observational study for patients at risk of chronic graft-versus-host disease

A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Observational Incyte Corporation · NCT05919511

This study is tracking the health of people who have recently had a stem cell transplant to see if they develop chronic graft-versus-host disease over the next few months.

Quick facts

Study typeObservational
Enrollment1500 (estimated)
Ages18 Years and up
SexAll
SponsorIncyte Corporation Industry-sponsored
Locations32 sites (Birmingham, Alabama and 31 other locations)
Trial IDNCT05919511 on ClinicalTrials.gov

What this trial studies

This observational study aims to gather data from individuals who have recently undergone an allogenic stem cell transplant and are at risk for developing chronic graft-versus-host disease (cGVHD). Participants will be monitored for 90 to 180 days post-transplant to assess their health and any signs of cGVHD. The study is non-interventional, meaning no additional treatments will be administered as part of the study. Data collected will help improve understanding and management of cGVHD in transplant patients.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older who have undergone an allogeneic stem cell transplant within the last 90 to 180 days.

Not a fit: Patients who have not had an allogeneic stem cell transplant or are outside the specified time frame will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the understanding of cGVHD and lead to better management strategies for patients at risk.

How similar studies have performed: While this study is observational, similar studies have successfully contributed to the understanding of cGVHD and its management.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Age ≥ 18 years inclusive at the time of signing the ICF
* Allogeneic SCT 90 to 180 days prior to enrollment
* Able to comprehend and willing to provide informed consent
* Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel

Exclusion Criteria:

* There are no exclusion criteria for this study

Where this trial is running

Birmingham, Alabama and 31 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions cGVHDchronic graft versus host diseaseMA-GVHD-401THRIVEGVHDchronic GVHDallogenic stem cell transplant
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.